Polio vaccine attenuated vaccine strains. In 1958, the National Institutes of Health created a special committee on live polio vaccines. The various vaccines were carefully evaluated for their ability to induce immunity to polio, while retaining a low incidence of neuropathogenicity in monkeys. Large-scale clinical trials performed in the Soviet Union in late 1950s to early 1960s by Mikhail Chumakov and his colleagues demonstrated safety and high efficacy of the vaccine. Based on these results, the Sabin strains were chosen for worldwide distribution. Fifty-seven nucleotide substitutions distinguish the attenuated Sabin 1 strain from its virulent parent (the Mahoney serotype), two nucleotide substitutions
Albert Sabin to Sabin, as well as assuming the middle name Bruce. Sabin received a medical degree from New York University in 1931. He trained in internal medicine, pathology, and surgery at Bellevue Hospital in New York City from 1931–1933. In 1934, he conducted research at The Lister Institute for Preventive Medicine in England, then joined the Rockefeller Institute for Medical Research (now Rockefeller University). During this time, he developed an intense interest in research, especially in the area of infectious diseases. In 1939, he moved to Cincinnati Children's Hospital in Cincinnati, Ohio. During World War II, he was a lieutenant colonel